Researchers developed a computational-experimental pipeline that identified a proteasome-spliced peptide carrying the KRAS G12V cancer mutation, which binds the most common HLA type and could enable immunotherapy for a broader patient population.
HLA-A*02:01 binding confirmedThe identified KRAS G12V spliced peptide binds efficiently to the most prevalent HLA class I molecule, potentially making it useful for immunotherapy in a large proportion of cancer patients.
What the researchers found
The pipeline identified a KRAS G12V mutation-carrying spliced epitope that is produced by proteasomes, transported by TAP proteins, and efficiently presented on cell surfaces by HLA-A*02:01 complexes — the most prevalent HLA class I molecule.
This is significant because conventional (non-spliced) peptides from the KRAS G12V mutation have low affinity for predominant HLA types, limiting their use in immunotherapy to only a few patients. By leveraging the much larger diversity of proteasome-generated spliced peptides, this approach could enable T cell-based immunotherapies targeting KRAS mutations in large cohorts of cancer patients.
Why it matters
KRAS mutations are among the most common cancer-driving mutations, found in pancreatic, colorectal, and lung cancers. However, targeting them with immunotherapy has been challenging because the mutated peptides don't display well on common HLA types. This pipeline opens up a new strategy — using spliced peptides — that dramatically expands the pool of targetable epitopes and the number of patients who could benefit from KRAS-directed immunotherapy.
How the study worked
The researchers developed an in silico-in vitro pipeline that first computationally predicted which spliced peptides carrying the KRAS G12V mutation would bind strongly to HLA-A*02:01. They then validated the candidates experimentally, confirming that the identified peptide is produced by proteasomes, transported by TAP proteins, and efficiently presented on HLA-A*02:01 complexes. The study used structural modeling and binding assays as part of the validation.
What this study cannot tell us
This is a proof-of-principle study; the identified spliced epitope has not been tested for its ability to activate T cells in cancer patients. The pipeline's predictions need validation in clinical settings. The study focused on a single mutation (KRAS G12V) and a single HLA allele (HLA-A*02:01). The efficiency of spliced peptide generation by proteasomes in tumor cells in vivo remains to be confirmed. No clinical or animal model data were presented.
How to read the evidence
This is an early-stage proof-of-principle study combining computational prediction with in vitro validation. While the pipeline is innovative and the results are promising, no T cell activation or in vivo data were presented, placing this at a preclinical discovery stage.
When this study was published
Published in 2019, this study was among the first to systematically explore proteasome-spliced peptides as cancer immunotherapy targets. The field has since continued to develop spliced peptide-based approaches.
The bigger picture
Proteasome-generated spliced peptides represent a vastly underexplored source of immune targets. While most cancer immunotherapy research focuses on conventional peptides, spliced peptides could exponentially increase the number of targetable epitopes. This study provides proof of concept that a systematic pipeline can identify clinically relevant spliced epitopes, with implications not just for KRAS-mutant cancers but for immunotherapy design more broadly.
Questions still open
- Can this spliced peptide effectively activate cytotoxic T cells against KRAS G12V-mutant tumor cells in patients?
- How many additional cancer-relevant spliced epitopes could this pipeline identify for other common mutations?
- Will proteasome splicing efficiency in actual tumor cells be sufficient for reliable immune recognition?
Common questions
What are spliced peptides and why do they matter for cancer treatment?
Why is targeting KRAS mutations important in cancer?
Read the original research
An in silico-in vitro Pipeline Identifying an HLA-A*02:01+ KRAS G12V+ Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients.
Frontiers in immunology, 10, 2572
Citation
Mishto, Michele; Mansurkhodzhaev, Artem; Ying, Ge; Bitra, Aruna; Cordfunke, Robert A; Henze, Sarah; Paul, Debdas; Sidney, John; Urlaub, Henning; Neefjes, Jacques; Sette, Alessandro; Zajonc, Dirk M; Liepe, Juliane. (2019). An in silico-in vitro Pipeline Identifying an HLA-A*02:01+ KRAS G12V+ Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients.. Frontiers in immunology, 10, 2572. https://doi.org/10.3389/fimmu.2019.02572